Peptide Therapeutics Market to surpass US$ 45.0 billion by 2026: CMI
Peptide therapeutics have wide range of applications in medicine and biotechnology and therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1) agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative market growth, as Victoza from Novo Nordisk, is the most prominent member of the class, reaching blockbuster status. Moreover, main area currently driving the growth of peptide therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore, peptide therapeutics are in clinical testing for infectious diseases and inflammation. Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1837
★
★
★
★
★
184 views • 8 slides
